DK2983787T3 - Fremgangsmåde til behandling af posttraumatisk stresssygdom - Google Patents
Fremgangsmåde til behandling af posttraumatisk stresssygdom Download PDFInfo
- Publication number
- DK2983787T3 DK2983787T3 DK14783146.5T DK14783146T DK2983787T3 DK 2983787 T3 DK2983787 T3 DK 2983787T3 DK 14783146 T DK14783146 T DK 14783146T DK 2983787 T3 DK2983787 T3 DK 2983787T3
- Authority
- DK
- Denmark
- Prior art keywords
- post
- procedure
- treatment
- stress disorder
- traumatic stress
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heat Treatment Of Articles (AREA)
- Heat Treatment Of Strip Materials And Filament Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811681P | 2013-04-12 | 2013-04-12 | |
| US201361915947P | 2013-12-13 | 2013-12-13 | |
| PCT/US2014/033997 WO2014169272A1 (en) | 2013-04-12 | 2014-04-14 | Method for treating post-traumatic stress disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2983787T3 true DK2983787T3 (da) | 2020-01-06 |
Family
ID=51690056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14783146.5T DK2983787T3 (da) | 2013-04-12 | 2014-04-14 | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20160067196A1 (da) |
| EP (1) | EP2983787B1 (da) |
| JP (1) | JP6462663B2 (da) |
| KR (3) | KR20220044380A (da) |
| CN (2) | CN112057441A (da) |
| AU (1) | AU2014250756B2 (da) |
| CA (1) | CA2909357C (da) |
| DK (1) | DK2983787T3 (da) |
| ES (1) | ES2760251T3 (da) |
| IL (1) | IL242007B (da) |
| MX (1) | MX370506B (da) |
| NZ (1) | NZ713300A (da) |
| PL (1) | PL2983787T3 (da) |
| WO (1) | WO2014169272A1 (da) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| EP2983787B1 (en) | 2013-04-12 | 2019-10-02 | Icahn School of Medicine at Mount Sinai | Method for treating post-traumatic stress disorder |
| WO2015037248A1 (en) | 2013-09-13 | 2015-03-19 | National University Corporation Chiba University | Application of r-ketamine and salt thereof as pharmaceuticals |
| CA2957926A1 (en) | 2014-08-13 | 2016-02-18 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| KR20170054470A (ko) | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
| EP3240422A1 (en) * | 2014-12-31 | 2017-11-08 | Icahn School of Medicine at Mount Sinai | Method of maintaining the anti-depressant effect of ketamine with lithium |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| CN106562952B (zh) * | 2015-10-09 | 2020-06-09 | 江阴安博生物医药有限公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
| WO2017087691A1 (en) * | 2015-11-17 | 2017-05-26 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| WO2017139382A1 (en) * | 2016-02-08 | 2017-08-17 | The Texas A&M University System | Combination of adjuvant drugs esketamine and brimonidine for medical treatments |
| US11213494B2 (en) * | 2016-03-24 | 2022-01-04 | Case Western Reserve University | Compositions and methods for the treatment of pervasive development disorders |
| US20180177744A1 (en) * | 2016-12-22 | 2018-06-28 | Gary Jay | Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| US12090123B2 (en) * | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| CN111630026A (zh) | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| IL275482B1 (en) | 2017-12-22 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| EP3753557B1 (en) | 2018-02-15 | 2025-11-05 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| KR101880731B1 (ko) | 2018-02-21 | 2018-07-20 | 주식회사 엠쓰리솔루션 | 외상 후 스트레스 극복용 컨텐츠 제공 시스템 |
| EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| EP3813807A1 (en) | 2018-06-27 | 2021-05-05 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| US12364672B2 (en) | 2018-10-11 | 2025-07-22 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| JP2022541872A (ja) * | 2019-05-31 | 2022-09-28 | セロン ファーマ エス．アー． | 医薬組成物の電子的に監督された非経口投与のための吸入器 |
| WO2020252384A1 (en) * | 2019-06-14 | 2020-12-17 | Vorsanger Gary | Treatment methods utilizing oxytocin receptor agonists |
| WO2021070120A1 (en) | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
| HUP1900358A1 (hu) | 2019-10-12 | 2021-04-28 | Meditop Gyogyszeripari Kft | Lamotrigin és szertralin hatóanyag tartalmú gyógyszerkészítmények, ezek elõállítása és alkalmazása |
| IL293506A (en) | 2019-12-30 | 2022-08-01 | Clexio Biosciences Ltd | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| CN115135317A (zh) | 2020-01-22 | 2022-09-30 | 西洛斯治疗有限公司 | 减少nmda拮抗剂的副作用 |
| CA3176225A1 (en) * | 2020-04-20 | 2021-10-28 | Maghsoud Dariani | Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury |
| WO2021257500A1 (en) * | 2020-06-17 | 2021-12-23 | Lobe Sciences Ltd. | Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder |
| US12369883B2 (en) | 2020-06-19 | 2025-07-29 | Ultrasound AI, Inc. | Artificial intelligence system for determining clinical values through medical imaging |
| US11266376B2 (en) | 2020-06-19 | 2022-03-08 | Ultrasound Ai Inc. | Premature birth prediction |
| US11382873B1 (en) * | 2021-01-08 | 2022-07-12 | Vitalis Analgesics LLC | Oral administration of ketamine |
| AU2022267377A1 (en) * | 2021-04-30 | 2023-12-14 | Progressive Therapeutics, Inc. | Ketamine and cannabis for the treatment of emotional disorders |
| TW202310825A (zh) * | 2021-05-14 | 2023-03-16 | 美商西羅斯醫療公司 | 減少ｎｍｄａ受體拮抗劑之副作用 |
| CN113967416A (zh) * | 2021-10-29 | 2022-01-25 | 新疆医科大学第四附属医院 | 一种高浓度对氯苯丙氨酸的溶解方法及应用 |
| EP4656194A1 (en) * | 2023-01-25 | 2025-12-03 | Aribio Co., Ltd | Composition for preventing or treating post-traumatic stress disorder, comprising phosphodiesterase type 5 inhibitor as active ingredient |
| KR20250161553A (ko) * | 2023-03-13 | 2025-11-17 | 울트라사운드 에이아이, 인코포레이티드 | 의료 이미징을 통한 포괄적인 의료 진단, 예후, 및 치료 최적화를 위한 인공 지능 시스템 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| MXPA05000294A (es) | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| WO2004045601A1 (en) * | 2002-11-18 | 2004-06-03 | Yaupon Therapeutics, Inc. | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
| US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
| BRPI0607017B8 (pt) * | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2008118785A2 (en) * | 2007-03-23 | 2008-10-02 | Tikvah Therapeutics | Methods for treating depression using immediate-impact treatments and d-cycloserine |
| US9808509B2 (en) | 2007-06-08 | 2017-11-07 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
| US20100298305A1 (en) * | 2008-11-26 | 2010-11-25 | The United States Government, As Represented By The Department Of Veterans Affairs | Tizanidine for the treatment of post-traumatic stress disorder and nightmares |
| WO2013085849A2 (en) * | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Sulfate esters of noribogaine |
| CN104114714A (zh) * | 2011-12-14 | 2014-10-22 | 阿斯利康(瑞典)有限公司 | Gabr-a2诊断 |
| US20130236573A1 (en) | 2012-03-12 | 2013-09-12 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| WO2014020155A1 (en) * | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| SG11201501292UA (en) | 2012-08-23 | 2015-05-28 | Stuart L Weg | Anxiolytic composition, formulation and method of use |
| EP2983787B1 (en) | 2013-04-12 | 2019-10-02 | Icahn School of Medicine at Mount Sinai | Method for treating post-traumatic stress disorder |
| WO2018191482A2 (en) | 2017-04-13 | 2018-10-18 | Ovid Therapeutics Inc. | Methods of treating developmental encephalopathies |
| US20200276186A1 (en) | 2017-11-20 | 2020-09-03 | Phoenix Pharmalabs, Inc. | Use of morphinans for treating cocaine addiction, pruritis, and seizure disorders |
| EP3930841A4 (en) | 2019-02-25 | 2022-11-30 | Zogenix International Limited | A formulation for improving seizure control |
| JP2024520510A (ja) | 2021-05-28 | 2024-05-24 | アイカーン スクール オブ メディスン アット マウント サイナイ | 薬物抵抗性てんかんを処置する方法 |
-
2014
- 2014-04-14 EP EP14783146.5A patent/EP2983787B1/en active Active
- 2014-04-14 WO PCT/US2014/033997 patent/WO2014169272A1/en not_active Ceased
- 2014-04-14 CA CA2909357A patent/CA2909357C/en active Active
- 2014-04-14 DK DK14783146.5T patent/DK2983787T3/da active
- 2014-04-14 JP JP2016507700A patent/JP6462663B2/ja active Active
- 2014-04-14 ES ES14783146T patent/ES2760251T3/es active Active
- 2014-04-14 AU AU2014250756A patent/AU2014250756B2/en active Active
- 2014-04-14 PL PL14783146T patent/PL2983787T3/pl unknown
- 2014-04-14 US US14/783,686 patent/US20160067196A1/en not_active Abandoned
- 2014-04-14 KR KR1020227010053A patent/KR20220044380A/ko not_active Ceased
- 2014-04-14 CN CN202010884736.5A patent/CN112057441A/zh active Pending
- 2014-04-14 KR KR1020217013044A patent/KR102424765B1/ko active Active
- 2014-04-14 NZ NZ713300A patent/NZ713300A/en unknown
- 2014-04-14 CN CN201480033664.6A patent/CN105377371A/zh active Pending
- 2014-04-14 KR KR1020157032043A patent/KR20150142012A/ko not_active Ceased
- 2014-04-14 MX MX2015014385A patent/MX370506B/es active IP Right Grant
-
2015
- 2015-10-11 IL IL242007A patent/IL242007B/en active IP Right Grant
- 2015-12-18 US US14/974,576 patent/US10478405B2/en active Active
-
2019
- 2019-11-05 US US16/674,381 patent/US11771661B2/en active Active
-
2023
- 2023-08-07 US US18/366,183 patent/US12403101B2/en active Active
-
2025
- 2025-07-25 US US19/280,606 patent/US20250345291A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL242007B (en) | 2020-08-31 |
| US20230381118A1 (en) | 2023-11-30 |
| US10478405B2 (en) | 2019-11-19 |
| KR20210050599A (ko) | 2021-05-07 |
| KR20220044380A (ko) | 2022-04-07 |
| AU2014250756A1 (en) | 2015-11-05 |
| MX370506B (es) | 2019-12-16 |
| KR102424765B1 (ko) | 2022-07-22 |
| JP2016516782A (ja) | 2016-06-09 |
| CN112057441A (zh) | 2020-12-11 |
| WO2014169272A1 (en) | 2014-10-16 |
| JP6462663B2 (ja) | 2019-01-30 |
| CA2909357A1 (en) | 2014-10-16 |
| NZ713300A (en) | 2020-05-29 |
| AU2014250756B2 (en) | 2019-03-07 |
| US20160067196A1 (en) | 2016-03-10 |
| EP2983787B1 (en) | 2019-10-02 |
| US20160101069A1 (en) | 2016-04-14 |
| US20250345291A1 (en) | 2025-11-13 |
| US12403101B2 (en) | 2025-09-02 |
| EP2983787A4 (en) | 2017-01-18 |
| EP2983787A1 (en) | 2016-02-17 |
| KR20150142012A (ko) | 2015-12-21 |
| US20200147006A1 (en) | 2020-05-14 |
| CA2909357C (en) | 2022-02-22 |
| MX2015014385A (es) | 2016-06-21 |
| CN105377371A (zh) | 2016-03-02 |
| US11771661B2 (en) | 2023-10-03 |
| ES2760251T3 (es) | 2020-05-13 |
| PL2983787T3 (pl) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
| DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
| DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
| DK2954051T3 (da) | Modificeret kapsid til genoverførsel til behandling af nethinden | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK2994159T3 (da) | Forudsigelse af t-celleepitopers immunogenicitet | |
| DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK2976359T4 (da) | Fremgangsmåder til behandling af osteogenesis imperfecta | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3062811T3 (da) | Angiopoietin-baserede interventioner til behandling af cerebral malaria | |
| DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme |